B lymphocyte signaling pathways in systemic autoimmunity: Implications for pathogenesis and treatment

Arthritis and Rheumatism

Volumn 50, Issue 9, 2004, Pages 2730-2741

  Zouali, Moncef ^a   Sarmay, Gabriella ^b  

^a INSERM   (France)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIGEN; B LYMPHOCYTE RECEPTOR; CD19 ANTIGEN; CD22 ANTIGEN; CD31 ANTIGEN; CD45 ANTIGEN; FC GAMMA RECEPTOR IIB; FC RECEPTOR; PD 1 PROTEIN; PROTEIN KINASE C DELTA; PROTEIN KINASE LYN; PROTEIN TYROSINE PHOSPHATASE SHP 1; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; GENE; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LYN GENE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANTIGENS, CD; ANTIGENS, CD19; ANTIGENS, CD22; ANTIGENS, CD31; ANTIGENS, CD45; ANTIGENS, DIFFERENTIATION; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-LYMPHOCYTES; CELL ADHESION MOLECULES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LECTINS; PROTEIN KINASE C; PROTEIN KINASE C-DELTA; PROTEIN-TYROSINE-PHOSPHATASE; RECEPTORS, ANTIGEN, B-CELL; RECEPTORS, IGG; SHP1 PROTEIN TYROSINE PHOSPHATASE; SIGNAL TRANSDUCTION;

EID: 4444274754     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20487     Document Type: Review

References (58)

1. Reth M, Wienands J. Initiation and processing of signals from the B cell antigen receptor. Annu Rev Immunol 1997;15:453-79.
2. Benschop RJ, Gambier JC. B cell development: signal transduction by antigen receptors and their surrogates. Curr Opin Immunol 1999;11:143-51.
3. Hasler P, Zouali M. B cell receptor signaling and autoimmunity. Faseb J 2001;15:2085-98.
4. Kammer GM, Perl A, Richardson BC, Tsokos GC. Abnormal T cell signal transduction in systemic lupus erythematosus. Arthritis Rheum 2002;46:1139-54.
5. Yu CC, Mamchak AA, DeFranco AL. Signaling mutations and autoimmunity. Curr Dir Autoimmun 2003;6:61-88.
6. Liossis SN, Zouali M. B lymphocyte selection and survival in systemic lupus. Int Arch Allergy Immunol 2004;133:72-83.
7. Hibbs ML, Tarlinton DM, Armes J, Grail D, Hodgson G, Maglitto R, et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 1995;83:301-11.
8. Nishizumi H, Taniuchi I, Yamanashi Y, Kitamura D, Ilic D, Mori S, et al. Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice. Immunity 1995;3:549-60.
9. Du C, Sriram S. Increased severity of experimental allergic encephalomyelitis in lyn-/- mice in the absence of elevated proinflammatory cytokine response in the central nervous system. J Immunol 2002;168:3105-12.
10. Cornall RJ, Cyster JG, Hibbs ML, Dunn AR, Otipoby KL, Clark EA, et al. Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity 1998;8:497-508.
11. Hibbs ML, Harder KW, Armes J, Kountouri N, Quilici C, Casagranda F, et al. Sustained activation of Lyn tyrosine kinase in vivo leads to autoimmunity. J Exp Med 2002;196:1593-604.
12. Majeti R, Xu Z, Parslow TG, Olson JL, Daikh DI, Killeen N, et al. An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity. Cell 2000;103:1059-70.
13. Shultz LD, Schweitzer PA, Rajan TV, Yi T, Ihle JN, Matthews RJ, et al. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell 1993;73:1445-54.
14. Tsui HW, Siminovitch KA, de Souza L, Tsui FW. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat Genet 1993;4:124-9.
15. Mecklenbrauker I, Saijo K, Zheng NY, Leitges M, Tarakhovsky A. Protein kinase Cδ controls self-antigen-induced B-cell tolerance. Nature 2002;416:860-5.
16. Miyamoto A, Nakayama K, Imaki H, Hirose S, Jiang Y, Abe M, et al. Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cδ. Nature 2002;416:865-9.
17. Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y, et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002;109:1453-62.
18. Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000;165:6635-43.
19. Daeron M. Fc receptor biology. Annu Rev Immunol 1997;15:203-34.
20. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001;19:275-90.
21. Radic MZ, Zonali M. Receptor editing, immune diversification and self-tolerance. Immunity 1996;5:505-11.
22. Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2002;2:580-92.
23. Yajima K, Nakamura A, Sugahara A, Takai T. FcγRIIB deficiency with Fas mutation is sufficient for the development of systemic autoimmune disease. Eur J Immunol 2003;33:1020-9.
24. Jiang Y, Hirose S, Abe M, Sanokawa-Akakura R, Ohtsuji M, Mi X, et al. Polymorphisms in IgG Fc receptor IIB regulatory regions associated with autoimmune susceptibility. Immunogenetics 2000;51:429-35.
25. Pritchard NR, Cutler AJ, Uribe S, Chadban SJ, Morley BJ, Smith KG. Autoimmune-prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor FcγRII. Curr Biol 2000;10:227-30.
26. Radic MZ, Weigert M. Genetic and structural evidence for antigen selection of anti-DNA antibodies. Annu Rev Immunol 1994;12:487-520.
27. Demaison C, Chastagner P, Theze J, Zouali M. Somatic diversification in the heavy chain variable region genes expressed by human autoantibodies bearing a lupus-associated nephritogenic anti-DNA idiotype. Proc Natl Acad Sci U S A 1994;91:514-8.
28. Nitschke L, Floyd H, Ferguson DJ, Crocker PR. Identification of CD22 ligands on bone marrow sinusoidal endothelium implicated in CD22-dependent homing of recirculating B cells. J Exp Med 1999;189:1513-8.
29. Lajaunias F, Nitschke L, Moll T, Martinez-Soria E, Semac I, Chicheportiche Y, et al. Differentially regulated expression and function of CD22 in activated B-1 and B-2 lymphocytes. J Immunol 2002;168:6078-83.
30. Sato S, Miller AS, Inaoki M, Bock CB, Jansen PJ, Tang ML, et al. CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity 1996;5:551-62.
31. O'Keefe TL, Williams GT, Batista FD, Neuberger MS. Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med 1999;189:1307-13.
32. Nitschke L, Carsetti R, Ocker B, Kohler G, Lamers MC. CD22 is a negative regulator of B-cell receptor signalling. Curr Biol 1997;7:133-43.
33. Wakeland EK, Liu K, Graham RR, Behrens TW. Delineating the genetic basis of systemic lupus erythematosus. Immunity 2001;15:397-408.
34. Mary C, Laporte C, Parzy D. Santiago ML, Stefani F, Lajaunias F, et al. Dysregulated expression of the Cd22 gene as a result of a short interspersed nucleotide element insertion in Cd22a lupus-prone mice. J Immunol 2000;165:2987-96.
35. Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 2001;22:265-8.
36. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A 2001;98:13866-71.
37. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141-51.
38. Henshall TL, Jones KL, Wilkinson R, Jackson DE. Src homology 2 domain-containing protein-tyrosine phosphatases, SHP-1 and SHP-2, are required for platelet endothelial cell adhesion molecule-1/CD31-mediated inhibitory signaling. J Immunol 2001;166:3098-106.
39. Wilkinson R, Lyons AB, Roberts D, Wong MX, Bartley PA, Jackson DE. Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) acts as a regulator of B-cell development, B-cell antigen receptor (BCR)-mediated activation, and auto-immune disease. Blood 2002;100:184-93.
40. Liossis SN, Kovacs B, Dennis G, Kammer GM, Tsokos GC. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest 1996;98:2549-57.
41. Huck S, Le Corre R, Youinou P, Zouali M. Expression of B cell receptor-associated signaling molecules in human lupus. Autoimmunity 2001;33:213-24.
42. Liossis SN, Solomou EE, Dimopoulos MA, Panayiotidis P, Mavrikakis MM, Sfikakis PP. B-cell kinase lyn deficiency in patients with systemic lupus erythematosus. J Investig Med 2001;49:157-65.
43. Hatta Y, Tsuchiya N, Matsushita M, Shiota M, Hagiwara K, Tokunaga K. Identification of the gene variations in human CD22. Immunogenetics 1999;49:280-6.
44. Kuroki K, Tsuchiya N, Tsao BP, Grossman JM, Fukazawa T, Hagiwara K, et al. Polymorphisms of human CD19 gene: possible association with susceptibility to systemic lupus erythematosus in Japanese. Genes Immun 2002;3 Suppl 1:S21-30.
45. Tsao BP, Cantor RM, Kalunian KC, Chen CJ, Badsha H, Singh R, et al. Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. J Clin Invest 1997;99:725-31.
46. Kyogoku C, Dijstelbloem HM, Tsuchiya N, Hatta Y, Kato H, Yamaguchi A, et al. Fcy receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum 2002;46:1242-54.
47. Li X, Wu J, Carter RH, Edberg JC, Su K, Cooper GS, et al. A novel polymorphism in the Fcγ receptor IIB (CD32B) transmembrane region alters receptor signaling. Arthritis Rheum 2003;48:3242-52.
48. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002;32:666-9.
49. Brundula V, Rivas LJ, Blasini AM, Paris M, Salazar S, Stekman IL, et al. Diminished levels of T cell receptor ζ chains in peripheral blood T lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 1999;42:1908-16.
50. Zouali M. Signaling in human lupus T lymphocytes. Lupus 1998;7:499-502.
51. Zouali M. Systemic lupus: taming the red wolf. Scientific American. In press.
52. Grammer AC, Slota R, Fischer R, Gur H, Girschick H, Yarboro C, et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 2003;112:1506-20.
53. Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:3251-8.
54. Patel DD. B cell-ablative therapy for the treatment of autoimmune diseases. Arthritis Rheum 2002;46:1984-5.
55. Clohisy JC, Roy BC, Biondo C, Frazier E, Willis D, Teitelbaum SL, et al. Direct inhibition of NF-κB blocks bone erosion associated with inflammatory arthritis. J Immunol 2003;171:5547-53.
56. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-25.
57. Tamir I, Stolpa JC, Helgason CD, Nakamura K, Brunns P, Daeron M, et al. The RasGAP-binding protein p62dok is a mediator of inhibitory FcγRIIB signals in B cells. Immunity 2000;12:347-58.
58. Koncz G, Toth GK, Bokonyi G, Keri G, Pecht I, Medgyesi D, et al. Co-clustering of Fey and B cell receptors induces dephosphorylation of the Grb2-associated binder 1 docking protein. Eur J Biochem 2001;268:3898-906.